Skip to main content

TableĀ 1 Summary of human studies of the BDNF promotersā€™ DNA methylation in psychiatric disorders

From: BDNF DNA methylation changes as a biomarker of psychiatric disorders: literature review and open access database analysis

Reference

Year

BDNF region

Chromosomal position (hg19)

Phenotype

Tissue

Samples

Method

Statistical power

Fuchikami et al.

2011

Promoter I Promoter IV

chr11:27743473ā€“27744564

chr11:27722840ā€“27723980

Major depression (MDD)

Peripheral blood

20 MDD, 18 CT

EpiTYPER

CpG8,9ā€”75.7Ā %

CpG76ā€”54.3Ā %

CpG80,81ā€”79.1Ā %

For rest CpGsā€”>80Ā %

Dā€™Addario et al.

2012

Promoter I

chr11:27744031ā€“27744193

Bipolar disorder I, II (BDI, BDII)

Peripheral blood

49 BD I, 45 BD II, 52 CT

Methylation-specific real-time PCR

BDII vs CTā€”62.5Ā %

Antidep. vs antidep-freeā€”93Ā %

Dā€™Addario et al.

2013

Promoter I

chr11:27744031ā€“27744193

Major depression

Peripheral blood

41 MDD, 44 CT

Methylation-specific real-time PCR

Methylation level ā€”83.1Ā %

Expression levelā€”65.9Ā %

Ikegame et al.

2013

Promoter I Promoter IV

chr11:27743390ā€“27743763

chr11:27722994ā€“27723372

Schizophrenia (SCZ)

Peripheral blood

100 SCZ, 100 CT

Bisulfite pyrosequencing

CpG72ā€”52.4Ā %

Perroud et al.

2013

Promoter I Promoter IV

chr11:27743862ā€“27744057

chr11:27723057ā€“27723293

Borderline personality disorder (BPD)

Peripheral blood

115 BPD, 52 CT

High resolution melt analysis

BPD vs CTā€”100Ā %

Dellā€™Osso et al.

2014

Promoter I

chr11:27744031ā€“27744194

Bipolar disorder I, II, major depression

Peripheral blood

43MDD, 61 BD I, 50 BD II, 44 CT

Methylation-specific real-time PCR

MDD, BDII vs BDI and CTā€”100Ā %

Kleimann et al.

2015

Promoter I Promoter IV Promoter VI

chr11:27743416ā€“27744782 (3 regions) chr11:27723103ā€“27723511

chr11:27722216ā€“27722863 (2 regions)

Treatment-resistant major depression (electroconvulsive therapy)

Peripheral blood

11MDD

Direct bisulfite sequencing

Remit. vs non-remit. 4 treatment sessions: 91ā€“100Ā %

Chagnon et al.

2015

Promoter I Exon III Promoter VI/Exon VI

NS

Anxiety/major depression

Saliva

19 MDD, 24 CT

Bisulfite pyrosequencing

MDD vs CTā€”86.3Ā %

CT gen. MDD vs CT gen. CTā€”88.3Ā %

Keller et al.

2010

Promoter IV

chr11:27723126ā€“27723144 (4 CpG sites)

Major depression, suicide

Brain (Wernicke area)

44 SU, 33 CT

Bisulfite pyrosequencing, direct bisulfite sequencing, EpiTYPER

CpG1ā€”98.1Ā %

CpG3ā€”96.3Ā %

Average levelā€”98.3Ā %

Kordi-Tamandani et al.

2012

Promoter IV

NS

Schizophrenia

Peripheral blood

80 SCZ, 71 CT

Methylation-specific PCR

Methylation levelā€”99Ā %

Expression levelā€”94Ā %

Tadic et al.

2014

Promoter IV

chr11:27723103ā€“27723380

Major depression (antidepressant treatment)

Peripheral blood

39 MDD

Direct bisulfite sequencing

NA

Thaler et al.

2014

Promoter IV

chr11:27722840ā€“27723980

Bulimic nervosa (BN),

Borderline personality disorder

Peripheral blood

64 BN(F), 32 CT

EpiTYPER

BN vs CTā€”in average for all CpG sitesā€”99.8Ā %

Kang et al.

2013

Promoter VI

chr11:27721688ā€“27721823

Major depressive, suicidal behavior (antidepressant treatment)

Peripheral blood

108 MDD

Bisulfite pyrosequencing

Previous suicidal attemptā€”76.7Ā %

Suicidal ideation during treatmentā€”83.6 and 96.6Ā %

Kang et al.

2015a

Promoter VI

chr11:27721688ā€“27721823

Depression related to breast cancer

Peripheral blood

74 D, 235 CT

Bisulfite pyrosequencing

D vs CT within 1Ā week and 1Ā year in averageā€”81.2Ā %

Kang et al.

2015b

Promoter VI

chr11:27721688ā€“27721823

Late-life depression

Peripheral blood

101 D, 631 CT

Bisulfite pyrosequencing

D vs CT at baseline and after 2Ā years in averageā€”97.7Ā %

Unternaehrer et al.

2015

Exon VI

chr11:27721543ā€“ 277221857

Low maternal care (LC) vs. high maternal care (HC)

Peripheral blood

45 LC, 40 HC

EpiTYPER

NA

Mill et al.

2008

Promoter IX

chr11:27679911ā€“27680006

Schizophrenia, bipolar disorder

Brain (frontal cortex)

35 SZ, 35 BD, 35 CT

Enriched unmethylated DNA microarray, bisulfite pyrosequencing

Val homozygotes (78) vs Met carries (27)ā€”100Ā %